Cargando…
MiR‐335‐5p restores cisplatin sensitivity in ovarian cancer cells through targeting BCL2L2
OBJECTIVE: Our study was designed to explore the association miR‐335‐5p and BCL2L2 and to investigate the influence of miR‐335‐5p/BCL2L2 axis on cisplatin‐resistant ovarian cancer cells. METHODS: Microarray analysis was used to determine differentially expressed microRNAs in primary and cisplatin‐re...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6143943/ https://www.ncbi.nlm.nih.gov/pubmed/30019389 http://dx.doi.org/10.1002/cam4.1682 |
_version_ | 1783356069659017216 |
---|---|
author | Liu, Ruonan Guo, Hailong Lu, Shifen |
author_facet | Liu, Ruonan Guo, Hailong Lu, Shifen |
author_sort | Liu, Ruonan |
collection | PubMed |
description | OBJECTIVE: Our study was designed to explore the association miR‐335‐5p and BCL2L2 and to investigate the influence of miR‐335‐5p/BCL2L2 axis on cisplatin‐resistant ovarian cancer cells. METHODS: Microarray analysis was used to determine differentially expressed microRNAs in primary and cisplatin‐resistant A2780 cells. Cell function experiments were conducted to investigate the effect of miR‐335‐5p on the cisplatin sensitivity of A2780 cells. The targeted relationship between BCL2L2 mRNA and miR‐335‐5p was validated through luciferase assay. Tumor xenograft was performed to confirm the function of miR‐335‐5p in restoring the cisplatin sensitivity of the ovarian cancer cells. RESULTS: MiR‐335‐5p was lowly expressed in cisplatin‐resistant A2780 cells. Overexpression of miR‐335‐5p reduced cell survival and enhanced cisplatin‐induced cell apoptosis. BCL2L2 mRNA was a target of miR‐335‐5p, and silencing of BCL2L2 showed the similar results on the cell viability as miR‐335‐5p overexpression. CONCLUSION: Upregulation of miR‐335‐5p expression enhanced the cisplatin sensitivity of ovarian cancer cells through suppressing BCL2L2, suggesting the potential of miR‐335‐5p/BCL2L2 axis as a therapeutic target for the cisplatin resistance of patients with ovarian cancer. |
format | Online Article Text |
id | pubmed-6143943 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-61439432018-09-24 MiR‐335‐5p restores cisplatin sensitivity in ovarian cancer cells through targeting BCL2L2 Liu, Ruonan Guo, Hailong Lu, Shifen Cancer Med Cancer Biology OBJECTIVE: Our study was designed to explore the association miR‐335‐5p and BCL2L2 and to investigate the influence of miR‐335‐5p/BCL2L2 axis on cisplatin‐resistant ovarian cancer cells. METHODS: Microarray analysis was used to determine differentially expressed microRNAs in primary and cisplatin‐resistant A2780 cells. Cell function experiments were conducted to investigate the effect of miR‐335‐5p on the cisplatin sensitivity of A2780 cells. The targeted relationship between BCL2L2 mRNA and miR‐335‐5p was validated through luciferase assay. Tumor xenograft was performed to confirm the function of miR‐335‐5p in restoring the cisplatin sensitivity of the ovarian cancer cells. RESULTS: MiR‐335‐5p was lowly expressed in cisplatin‐resistant A2780 cells. Overexpression of miR‐335‐5p reduced cell survival and enhanced cisplatin‐induced cell apoptosis. BCL2L2 mRNA was a target of miR‐335‐5p, and silencing of BCL2L2 showed the similar results on the cell viability as miR‐335‐5p overexpression. CONCLUSION: Upregulation of miR‐335‐5p expression enhanced the cisplatin sensitivity of ovarian cancer cells through suppressing BCL2L2, suggesting the potential of miR‐335‐5p/BCL2L2 axis as a therapeutic target for the cisplatin resistance of patients with ovarian cancer. John Wiley and Sons Inc. 2018-07-17 /pmc/articles/PMC6143943/ /pubmed/30019389 http://dx.doi.org/10.1002/cam4.1682 Text en © 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Cancer Biology Liu, Ruonan Guo, Hailong Lu, Shifen MiR‐335‐5p restores cisplatin sensitivity in ovarian cancer cells through targeting BCL2L2 |
title | MiR‐335‐5p restores cisplatin sensitivity in ovarian cancer cells through targeting BCL2L2
|
title_full | MiR‐335‐5p restores cisplatin sensitivity in ovarian cancer cells through targeting BCL2L2
|
title_fullStr | MiR‐335‐5p restores cisplatin sensitivity in ovarian cancer cells through targeting BCL2L2
|
title_full_unstemmed | MiR‐335‐5p restores cisplatin sensitivity in ovarian cancer cells through targeting BCL2L2
|
title_short | MiR‐335‐5p restores cisplatin sensitivity in ovarian cancer cells through targeting BCL2L2
|
title_sort | mir‐335‐5p restores cisplatin sensitivity in ovarian cancer cells through targeting bcl2l2 |
topic | Cancer Biology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6143943/ https://www.ncbi.nlm.nih.gov/pubmed/30019389 http://dx.doi.org/10.1002/cam4.1682 |
work_keys_str_mv | AT liuruonan mir3355prestorescisplatinsensitivityinovariancancercellsthroughtargetingbcl2l2 AT guohailong mir3355prestorescisplatinsensitivityinovariancancercellsthroughtargetingbcl2l2 AT lushifen mir3355prestorescisplatinsensitivityinovariancancercellsthroughtargetingbcl2l2 |